The tumour microenvironment as a target for chemoprevention (original) (raw)

• Farber, E. & Rubin, H. Cellular adaptation in the origin and development of cancer. Cancer Res. 51, 2751–2761 (1991).
  CAS PubMed Google Scholar
• Clark, W. H. Jr. The nature of cancer: morphogenesis and progressive (self)-disorganization in neoplastic development and progression. Acta Oncol. 34, 3–21 (1995).
  Article PubMed Google Scholar
• Sporn, M. B. The war on cancer. Lancet 347, 1377–1381 (1996).
  Article CAS PubMed Google Scholar
• Mueller, M. M. & Fusenig, N. E. Friends or foes- bipolar effects of the tumour stroma in cancer. Nature Rev. Cancer 4, 839–849 (2004).
  Article CAS Google Scholar
• Joyce, J. A. Therapeutic targeting of the tumor microenvironment. Cancer Cell 7, 513–520 (2005).
  Article CAS PubMed Google Scholar
• Bissell, M. J. & Labarge, M. A. Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? Cancer Cell 7, 17–23 (2005).
  CAS PubMed PubMed Central Google Scholar
• Bhowmick, N. A., Neilson, E. G. & Moses, H. L. Stromal fibroblasts in cancer initiation and progression. Nature 432, 332–337 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Bissell, M. J., Kenny, P. A. & Radisky, D. C. Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: the role of extracellular matrix and its degrading enzymes. Cold Spring Harb. Symp. Quant. Biol. 70, 1–14 (2005).
  Article Google Scholar
• Huang, S. & Ingber, D. E. A non-genetic basis for tumorigenesis and metastatic progression: self-organizing attractors in cell regulatory networks. Breast Dis. (in the press).
• Kumar, V., Abbas, A. K. & Fausto, N. Robbins and Cotran Pathologic Basis of Disease, 7th Edition 47–118 (Elsevier Saunders, Philadelphia, 2005).
  Google Scholar
• Dvorak, H. F. Angiogenesis: update 2005. J. Thromb. Haemost. 3, 1835–1842 (2005).
  Article CAS PubMed Google Scholar
• Albini, A., Tosetti, F., Benelli, R. & Noonan, D. M. Tumor inflammatory angiogenesis and its chemoprevention. Cancer Res. 65, 10637–10641 (2005).
  Article CAS PubMed Google Scholar
• Maruotti, N., Cantatore, F. P., Crivellato, E., Vacca, A. & Ribatti, D. Angiogenesis in rheumatoid arthritis. Histol. Histopathol. 21, 557–566 (2006).
  CAS PubMed Google Scholar
• Karin, M. Inflammation and cancer: the long reach of Ras. Nature Med. 11, 20–21 (2005).
  Article CAS PubMed Google Scholar
• Sparmann, A. & Bar-Sagi, D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6, 447–458 (2004).
  Article CAS PubMed Google Scholar
• Balkwill, F., Charles, K. A. & Mantovani, A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7, 211–217 (2005).
  Article CAS PubMed Google Scholar
• Lewis, C. E. & Pollard, J. W. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 66, 605–612 (2006).
  Article CAS PubMed Google Scholar
• Zhu, P. et al. Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell 124, 615–629 (2006).
  Article CAS PubMed Google Scholar
• Benelli, R., Albini, A. & Noonan, D. in The neutrophil: An emerging regulator of inflammatory and immune response (ed. M. A. Cassatella) 167–181 (Karger, Basel, 2003).
  Book Google Scholar
• Benelli, R. et al. Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation. FASEB J. 16, 267–269 (2002).
  Article CAS PubMed Google Scholar
• Scapini, P. et al. CXCL1/macrophage inflammatory protein-2-induced angiogenesis in vivo is mediated by neutrophil-derived vascular endothelial growth factor-A1. J. Immunol. 172, 5034–5040 (2004).
  Article CAS PubMed Google Scholar
• Kalluri, R. & Zeisberg, M. Fibroblasts in cancer. Nature Rev. Cancer 6, 392–401 (2006).
  Article CAS Google Scholar
• Orimo, A. et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335–348 (2005).
  Article CAS PubMed Google Scholar
• Powell, D. W. et al. Myofibroblasts. I. Paracrine cells important in health and disease. Am. J. Physiol. 277, C1–C9 (1999).
  Article CAS PubMed Google Scholar
• Shao, J., Sheng, G. G., Mifflin, R. C., Powell, D. W. & Sheng, H. Roles of myofibroblasts in prostaglandin E2-stimulated intestinal epithelial proliferation and angiogenesis. Cancer Res. 66, 846–855 (2006).
  Article CAS PubMed Google Scholar
• Calle, E. E., Rodriguez, C., Walker-Thurmond, K. & Thun, M. J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U. S. adults. N. Engl. J. Med. 348, 1625–1638 (2003).
  Article PubMed Google Scholar
• Calle, E. E. & Thun, M. J. Obesity and cancer. Oncogene 23, 6365–6378 (2004).
  Article CAS PubMed Google Scholar
• Wellen, K. E. & Hotamisligil, G. S. Inflammation, stress, and diabetes. J. Clin. Invest. 115, 1111–1119 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Comoglio, P. M. & Trusolino, L. Cancer: the matrix is now in control. Nature Med. 11, 1156–1159 (2005).
  Article CAS PubMed Google Scholar
• Grobstein, C. Inductive tissue interaction in development. Adv. Cancer Res. 4, 187–236 (1956).
  Article CAS PubMed Google Scholar
• Wiseman, B. S. & Werb, Z. Stromal effects on mammary gland development and breast cancer. Science 296, 1046–1049 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Allinen, M. et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 6, 17–32 (2004).
  Article CAS PubMed Google Scholar
• Ishiguro, K., Yoshida, T., Yagishita, H., Numata, Y. & Okayasu, T. Epithelial and stromal genetic instability contributes to genesis of colorectal adenomas. Gut 55, 695–702 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Weber, F. et al. Total-genome analysis of BRCA1/2-related invasive carcinomas of the breast identifies tumor stroma as potential landscaper for neoplastic initiation. Am. J. Hum. Genet. 78, 961–972 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Streubel, B. et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N. Engl. J. Med. 351, 250–259 (2004).
  Article CAS PubMed Google Scholar
• Hida, K. & Klagsbrun, M. A new perspective on tumor endothelial cells: unexpected chromosome and centrosome abnormalities. Cancer Res. 65, 2507–2510 (2005).
  Article CAS PubMed Google Scholar
• Kim, B. G. et al. Smad4 signalling in T cells is required for suppression of gastrointestinal cancer. Nature 441, 1015–1019 (2006).
  Article CAS PubMed Google Scholar
• Bindra, R. S. & Glazer, P. M. Genetic instability and the tumor microenvironment: towards the concept of microenvironment-induced mutagenesis. Mutat. Res. 569, 75–85 (2005).
  Article CAS PubMed Google Scholar
• Kelloff, G. J., Hawk, E. T. & Sigman, C. C., eds. Cancer chemoprevention: strategies for cancer chemoprevention (Humana Press, Totowa, NJ, 2005).
  Book Google Scholar
• Lippman, S. M. & Lee, J. J. Reducing the 'risk' of chemoprevention: defining and targeting high risk —2005 AACR Cancer Research and Prevention Foundation Award Lecture. Cancer Res. 66, 2893–2903 (2006).
  Article CAS PubMed Google Scholar
• De Flora, S. & Ferguson, L. R. Overview of mechanisms of cancer chemopreventive agents. Mutat. Res. 591, 8–15 (2005).
  Article CAS PubMed Google Scholar
• Sporn, M. B. & Liby, K. T. Cancer chemoprevention: scientific promise, clinical uncertainty. Nature Clin. Pract. Oncol. 2, 518–525 (2005).
  Article CAS Google Scholar
• Kelloff, G. J. et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer — a plan to move forward. Clin. Cancer Res. 12, 3661–3697 (2006).
  Article CAS PubMed Google Scholar
• Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860–867 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Balkwill, F. Cancer and the chemokine network. Nature Rev. Cancer 4, 540–550 (2004).
  Article CAS Google Scholar
• Condeelis, J. & Pollard, J. W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124, 263–266 (2006).
  Article CAS PubMed Google Scholar
• Karin, M. & Greten, F. R. NFκB: linking inflammation and immunity to cancer development and progression. Nature Rev. Immunol. 5, 749–759 (2005).
  Article CAS Google Scholar
• Mann, J. R., Backlund, M. G. & DuBois, R. N. Mechanisms of disease: inflammatory mediators and cancer prevention. Nature Clin. Pract. Oncol. 2, 202–210 (2005).
  Article CAS Google Scholar
• Suh, N. et al. Synthetic triterpenoids enhance transforming growth factor β/Smad signaling. Cancer Res. 63, 1371–1376 (2003).
  CAS PubMed Google Scholar
• Yu, H. & Jove, R. The STATs of cancer--new molecular targets come of age. Nature Rev. Cancer 4, 97–105 (2004).
  Article CAS Google Scholar
• Liby, K. et al. The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells. Clin. Cancer Res. 12, 4288–4293 (2006).
  Article CAS PubMed Google Scholar
• Dauer, D. J. et al. Stat3 regulates genes common to both wound healing and cancer. Oncogene 24, 3397–3408 (2005).
  Article CAS PubMed Google Scholar
• Palumbo, J. S. et al. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res. 62, 6966–6972 (2002).
  CAS PubMed Google Scholar
• Karin, M. NFκB and cancer: mechanisms and targets. Mol. Carcinog. 45, 355–361 (2006).
  Article CAS PubMed Google Scholar
• Aggarwal, S. et al. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IκBα kinase and Akt activation. Mol. Pharmacol. 69, 195–206 (2006).
  Article CAS PubMed Google Scholar
• Pfeffer, U. et al. Molecular mechanisms of action of angiopreventive anti-oxidants on endothelial cells: microarray gene expression analyses. Mutat. Res. 591, 198–211 (2005).
  Article CAS PubMed Google Scholar
• Singh, R. P., Dhanalakshmi, S., Agarwal, C. & Agarwal, R. Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NFκB: implications for angioprevention and antiangiogenic therapy. Oncogene 24, 1188–1202 (2005).
  Article CAS PubMed Google Scholar
• Albini, A. et al. Mechanisms of the antiangiogenic activity by the hop flavonoid xanthohumol: NFκB and Akt as targets. FASEB J. 20, 527–529 (2006).
  Article CAS PubMed Google Scholar
• Dell'eva, R. et al. The Akt inhibitor deguelin, is an angiopreventive agent also acting on the NFκB pathway. Carcinogenesis 4 September 2006 [epub ahead of print].
  Google Scholar
• Bertl, E., Bartsch, H. & Gerhauser, C. Inhibition of angiogenesis and endothelial cell functions are novel sulforaphane-mediated mechanisms in chemoprevention. Mol. Cancer Ther. 5, 575–585 (2006).
  Article CAS PubMed Google Scholar
• Xu, C., Shen, G., Chen, C., Gelinas, C. & Kong, A. N. Suppression of NF-κB and NF-κB-regulated gene expression by sulforaphane and PEITC through IκBα, IKK pathway in human prostate cancer PC-3 cells. Oncogene 24, 4486–4495 (2005).
  Article CAS PubMed Google Scholar
• Huang, S., DeGuzman, A., Bucana, C. D. & Fidler, I. J. Nuclear factor-κB activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice. Clin. Cancer Res. 6, 2573–2581 (2000).
  CAS PubMed Google Scholar
• Huang, S., Pettaway, C. A., Uehara, H., Bucana, C. D. & Fidler, I. J. Blockade of NF-κB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20, 4188–4197 (2001).
  Article CAS PubMed Google Scholar
• Reed, J. C. The Survivin saga goes in vivo. J. Clin. Invest. 108, 965–969 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Tran, J. et al. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc. Natl Acad. Sci. USA 99, 4349–4354 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• O'Connor, D. S. et al. Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am. J. Pathol. 156, 393–398 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Xiang, R. et al. A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res. 65, 553–561 (2005).
  CAS PubMed Google Scholar
• Tosetti, F., Ferrari, N., De Flora, S. & Albini, A. Angioprevention: angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J. 16, 2–14 (2002).
  Article CAS PubMed Google Scholar
• Brahimi-Horn, M. C. & Pouyssegur, J. The hypoxia-inducible factor and tumor progression along the angiogenic pathway. Int. Rev. Cytol. 242, 157–213 (2005).
  Article CAS PubMed Google Scholar
• Esteban, M. A. & Maxwell, P. H. HIF, a missing link between metabolism and cancer. Nature Med. 11, 1047–1048 (2005).
  Article CAS PubMed Google Scholar
• Semenza, G. L. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit. Rev. Biochem. Mol. Biol. 35, 71–103 (2000).
  Article CAS PubMed Google Scholar
• Cramer, T. et al. HIF-1α is essential for myeloid cell-mediated inflammation. Cell 112, 645–657 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Myzak, M. C., Dashwood, W. M., Orner, G. A., Ho, E. & Dashwood, R. H. Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus mice. FASEB J. 20, 506–508 (2006).
  Article CAS PubMed Google Scholar
• Kopelovich, L., Crowell, J. A. & Fay, J. R. The epigenome as a target for cancer chemoprevention. J. Natl Cancer Inst. 95, 1747–1757 (2003).
  Article CAS PubMed Google Scholar
• Kong, X. et al. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol. Cell Biol. 26, 2019–2028 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Fath, D. M. et al. Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-α. J. Biol. Chem. 281, 13612–13619 (2006).
  Article CAS PubMed Google Scholar
• Zhang, Q. et al. Green tea extract and (-)- epigallocatechin-3-gallate inhibit hypoxia- and serum-induced HIF-1α protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells. Mol. Cancer Ther. 5, 1227–1238 (2006).
  Article CAS PubMed Google Scholar
• Zhang, Q. et al. Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1α and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol. Cancer Ther. 4, 1465–1474 (2005).
  Article CAS PubMed Google Scholar
• Fang, J. et al. Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J. 19, 342–353 (2005).
  Article CAS PubMed Google Scholar
• Semenza, G. L. Targeting HIF-1 for cancer therapy. Nature Rev. Cancer 3, 721–732 (2003).
  Article CAS Google Scholar
• Blouw, B. et al. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4, 133–146 (2003).
  Article CAS PubMed Google Scholar
• Acker, T. et al. Genetic evidence for a tumor suppressor role of HIF-2α. Cancer Cell 8, 131–141 (2005).
  Article CAS PubMed Google Scholar
• Talalay, P., Dinkova-Kostova, A. T. & Holtzclaw, W. D. Importance of phase 2 gene regulation in protection against electrophile and reactive oxygen toxicity and carcinogenesis. Adv. Enzyme Regul. 43, 121–134 (2003).
  Article CAS PubMed Google Scholar
• Ryter, S. W., Alam, J. & Choi, A. M. Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol. Rev. 86, 583–650 (2006).
  Article CAS PubMed Google Scholar
• Zhang, Y. & Gordon, G. B. A strategy for cancer prevention: stimulation of the Nrf2-ARE signaling pathway. Mol. Cancer Ther. 3, 885–893 (2004).
  CAS PubMed Google Scholar
• Lee, J. S. & Surh, Y. J. Nrf2 as a novel molecular target for chemoprevention. Cancer Lett. 224, 171–184 (2005).
  Article CAS PubMed Google Scholar
• Buteau-Lozano, H., Ancelin, M., Lardeux, B., Milanini, J. & Perrot-Applanat, M. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors α and β. Cancer Res. 62, 4977–4984 (2002).
  CAS PubMed Google Scholar
• Loureiro, R. M. & D'Amore, P. A. Transcriptional regulation of vascular endothelial growth factor in cancer. Cytokine Growth Factor Rev. 16, 77–89 (2005).
  Article CAS PubMed Google Scholar
• Yen, W. C., Prudente, R. Y., Corpuz, M. R., Negro-Vilar, A. & Lamph, W. W. A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours. Br. J. Cancer 94, 654–660 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182–1186 (1971).
  Article CAS PubMed Google Scholar
• Carmeliet, P. Angiogenesis in life, disease and medicine. Nature 438, 932–936 (2005).
  Article CAS PubMed Google Scholar
• Kerbel, R. S. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312, 1171–1175 (2006).
  Article CAS PubMed Google Scholar
• Brown, J. R. & DuBois, R. N. COX-2: a molecular target for colorectal cancer prevention. J. Clin. Oncol. 23, 2840–2855 (2005).
  Article CAS PubMed Google Scholar
• Harris, R. E., Beebe-Donk, J. & Alshafie, G. A. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 6, 27 (2006).
  Article PubMed PubMed Central CAS Google Scholar
• Oshima, M. et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87, 803–809 (1996).
  Article CAS PubMed Google Scholar
• Masferrer, J. L. et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60, 1306–1311 (2000).
  CAS PubMed Google Scholar
• Donà, M. et al. Neutrophil restraint by green tea: inhibition of inflammation, associated angiogenesis, and pulmonary fibrosis. J. Immunol. 170, 4335–4341 (2003).
  Article PubMed Google Scholar
• Ferrari, N. et al. The transforming growth factor-beta family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl)retinamide. Clin. Cancer Res. 11, 4610–4619 (2005).
  Article CAS PubMed Google Scholar
• Shishodia, S., Gutierrez, A. M., Lotan, R. & Aggarwal, B. B. N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of IκBα kinase and nuclear factor-κB-regulated gene products. Cancer Res. 65, 9555–9565 (2005).
  Article CAS PubMed Google Scholar
• Veronesi, U. et al. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann. Oncol. 17, 1065–1071 (2006).
  Article CAS PubMed Google Scholar
• Demierre, M. F., Higgins, P. D., Gruber, S. B., Hawk, E. & Lippman, S. M. Statins and cancer prevention. Nature Rev. Cancer 5, 930–942 (2005).
  Article CAS Google Scholar
• Arber, N. et al. Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med. 355, 885–895 (2006).
  Article CAS PubMed Google Scholar
• Bertagnolli, M. M. et al. Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med. 355, 873–884 (2006).
  Article CAS PubMed Google Scholar
• Solomon, S. D. et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 114, 1028–1035 (2006).
  Article CAS PubMed Google Scholar
• Gail, M. H. & Costantino, J. P. Validating and improving models for projecting the absolute risk of breast cancer. J. Natl Cancer Inst. 93, 334–335 (2001).
  Article CAS PubMed Google Scholar
• Freedman, A. N. et al. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J. Natl Cancer Inst. 95, 526–532 (2003).
  Article CAS PubMed Google Scholar
• Szabo, E. Selecting targets for cancer prevention: where do we go from here? Nature Rev. Cancer 6, 867–874 (2006).
  Article CAS Google Scholar
• Hanahan, D. & Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353–364 (1996).
  Article CAS PubMed Google Scholar
• De Backer, G. et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur. J. Cardiovasc. Prev. Rehabil. 10, S1–S10 (2003).
  PubMed Google Scholar